Tabernanthe iboga is the Central African shrub from which ibogaine is extracted — but iboga contains dozens of alkaloids beyond ibogaine itself. Researchers are now investigating whether specific iboga alkaloids, synthetic analogs, and novel derivatives can preserve the plant's remarkable anti-addiction properties while dramatically reducing the cardiac toxicity that makes ibogaine one of the riskiest substances in psychedelic medicine.

What Makes Ibogaine Therapeutically Unique — and Dangerous?

Ibogaine's therapeutic reputation rests primarily on two effects: a dramatic interruption of opioid withdrawal symptoms and a sustained reduction in cravings across multiple substance use disorders. Mechanistically, ibogaine acts on an unusually wide array of targets — blocking NMDA receptors, modulating opioid receptors, inhibiting serotonin and dopamine reuptake, and promoting GDNF (glial cell line-derived neurotrophic factor) release, which may underpin long-term neuroplastic change.

The danger lies in ibogaine's potent hERG potassium channel blockade. This slows cardiac repolarization, measurably prolonging the QT interval on an electrocardiogram. A sufficiently prolonged QT interval can trigger torsades de pointes — a potentially fatal ventricular arrhythmia. A 2015 review in Molecules (Koenig & Hilber) identified hERG inhibition as the central mechanism behind ibogaine-associated fatalities, which cluster disproportionately in people with pre-existing cardiac risk factors or who used concurrent QT-prolonging substances.

Safety Note: Ibogaine-associated cardiac deaths have been documented in the medical literature. Cardiac screening — including a 12-lead ECG, electrolyte panel, and cardiology review — is considered a minimum safety standard at clinical settings globally. Ibogaine is Schedule I in the United States; possession and administration outside federally authorized research is illegal.

What Other Alkaloids Does Tabernanthe Iboga Contain?

The iboga plant produces a rich alkaloid profile. Ibogaine is the most abundant, but the root bark also contains noribogaine, tabernanthine, coronaridine, voacangine, and ibogamine, among others. Each has a distinct pharmacological fingerprint.

  • Noribogaine — ibogaine's primary active metabolite, formed in the liver. It has a longer half-life than ibogaine, is more selective for kappa-opioid receptors, and preliminary cardiac data suggests it may carry a lower QT-prolongation burden, though it is not benign.
  • Tabernanthine — structurally similar to ibogaine, with some overlapping receptor activity, but studied far less extensively in humans.
  • Coronaridine — the parent compound for 18-methoxycoronaridine (18-MC), a synthetic derivative that became a major research target in the 1990s.
  • Voacangine — found in higher concentrations in Voacanga africana, a related plant, and used as a semi-synthetic precursor to ibogaine in pharmaceutical manufacturing.

What Is 18-MC and Why Did Researchers Get Excited?

18-Methoxycoronaridine (18-MC) is a synthetic analog derived from coronaridine, developed by Stanley Glick and colleagues at Albany Medical College. In a foundational 1996 study published in Brain Research, Glick et al. showed that 18-MC reduced both morphine and cocaine self-administration in rats and decreased mesolimbic dopamine release — effects that parallel ibogaine's — while appearing to lack ibogaine's acute toxicity profile in animal models.

Critically, 18-MC is a selective alpha-3-beta-4 nicotinic acetylcholine receptor antagonist. This receptor subtype is heavily expressed in the medial habenula and interpeduncular nucleus — a circuit now understood to be centrally involved in addiction and withdrawal across multiple substances. Because 18-MC does not significantly block hERG channels at therapeutic-range doses in preclinical models, it attracted sustained attention as a potentially safer scaffold. DemeRx Inc. advanced 18-MC into Phase I/II clinical trials, though results have not yet produced a regulatory submission.

What About TBG — The "Non-Hallucinogenic" Ibogaine Analog?

A landmark 2020 paper in Nature (Cameron et al.) introduced tabernanthalog (TBG), a water-soluble, non-hallucinogenic synthetic iboga analog designed computationally to promote structural neural plasticity without engaging the serotonin 2A receptor pathway that drives psychedelic experience. In rodent models, TBG promoted dendritic spine growth, reduced alcohol and heroin self-administration, and showed no evidence of cardiac QT prolongation or the head-twitch response associated with serotonergic psychedelics.

TBG represents a philosophically different approach: rather than modifying the iboga plant's existing alkaloids, it uses ibogaine's structural skeleton as a starting point and engineers out both the cardiac liability and the visionary experience. Proponents argue this could enable outpatient, unsupervised treatment — a fundamental shift from ibogaine's current model of intensive clinical monitoring. Critics note that some researchers believe the visionary experience itself may be therapeutically meaningful, not merely a side effect to be eliminated.

Where Does the Stanford Veterans Study Fit In?

The most prominent recent clinical data on ibogaine's safety management comes from a Stanford-affiliated study of military veterans with traumatic brain injury and PTSD treated with ibogaine in licensed Mexican clinics. Researchers implemented rigorous cardiac monitoring protocols — continuous telemetry, magnesium preloading, and electrolyte optimization — and reported no serious cardiac events in the study cohort. The study, which drew significant media attention, demonstrated that with proper screening and monitoring, ibogaine's cardiac risk can be substantially mitigated in carefully selected populations.

This is important context for the "ibogaine without the cardiac risk" conversation: some researchers argue the goal should not be eliminating ibogaine in favor of analogs, but rather establishing standardized medical protocols that make ibogaine itself adequately safe for appropriate candidates. MAPS PBC has pursued this path, working toward FDA Breakthrough Therapy Designation for ibogaine-assisted therapy in specific indications.

Is Any Iboga Analog Close to Clinical Availability?

Currently, no iboga alkaloid analog has received FDA approval or completed Phase III trials. The development landscape looks like this:

  • 18-MC: Phase I/II human safety data exists; no Phase III trial is actively recruiting as of 2026.
  • TBG: Preclinical stage only; no published human data.
  • Noribogaine: Has been in early clinical trials (DemeRx); cardiac profile better than ibogaine but not fully characterized in large samples.
  • Ibogaine itself: The most clinically advanced, with ongoing trials under FDA-authorized IND protocols and active research programs in the US, Europe, and Australia.

The honest summary is that ibogaine's analogs remain years from any regulatory pathway to approval, while ibogaine itself — with its known risks — is accumulating the most real-world clinical data under supervised conditions.

Frequently Asked Questions

No. Tabernanthe iboga is the plant; ibogaine is one alkaloid extracted from it. The plant contains dozens of alkaloids with distinct pharmacological profiles. When people say they are taking "iboga" in a traditional Bwiti context, they are consuming the full-spectrum root bark, not purified ibogaine.
The cardiac risk from full-spectrum iboga root bark is not fully characterized and should not be assumed to be lower. The ibogaine content in root bark varies by plant preparation and batch. Cardiac fatalities have been documented with both root bark and purified ibogaine preparations. The same screening standards should apply.
The QT interval is the time it takes for your heart's ventricles to electrically reset after each beat, measured on an ECG. When this interval is prolonged — typically defined as a corrected QT (QTc) above 450ms in men or 470ms in women — the heart becomes vulnerable to a dangerous rhythm called torsades de pointes, which can degenerate into ventricular fibrillation. Ibogaine reliably prolongs QTc, sometimes substantially.
Noribogaine has been investigated in clinical trials as a standalone therapeutic. It shares some of ibogaine's receptor targets and produces less intense psychoactive effects. However, it still prolongs QTc and is not without cardiac liability. DemeRx conducted early-phase trials and reported dose-dependent QTc changes. It has not advanced to Phase III trials as of 2026.
No. TBG remains in preclinical research as of 2026. It has not entered human clinical trials. The 2020 Nature paper that described it was a preclinical study in rodent models. Any source claiming to offer TBG as a treatment would be operating entirely outside any regulatory or clinical framework.
This is precisely what medicinal chemists are attempting with analogs like 18-MC and TBG. The challenge is that ibogaine's complex, multi-receptor pharmacology is not cleanly separable from its cardiac liability at the molecular level using simple modifications. Each structural change ripples across the binding profile in ways that must be characterized from scratch, requiring years of preclinical safety testing before human trials.
Ibogaine is legal and available at licensed clinics in Mexico, the Netherlands, Portugal, Costa Rica, and several other countries. In the US, it remains Schedule I, meaning it cannot be prescribed or administered outside of FDA-authorized research. Participation in an active IND trial is the only legal route to ibogaine treatment within the United States. International options should be researched carefully, with emphasis on medical screening standards and cardiac monitoring protocols.

The search for an ibogaine analog without cardiac risk represents one of the most scientifically promising — and practically urgent — frontiers in addiction medicine. If you are researching treatment options for yourself or someone you care about, the safest path currently involves consulting with an addiction medicine specialist familiar with the ibogaine literature, a cardiologist who can assess individual cardiac risk, and, if pursuing treatment abroad, a clinic that conducts thorough pre-treatment screening including ECG evaluation and electrolyte assessment. No analog is ready to replace ibogaine in a clinical context today, but the science is moving quickly.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.